United Therapeutics price target raised to $150 from $120 at H.C. Wainwright H.C. Wainwright raised its price target for United Therapeutics shares to $150 citing strong sales and positive prospects following the company's Q2 results. The firm reiterates a Buy rating on the stock.
United Therapeutics agrees to sell PPRV to AbbVie for $350M United Therapeutics (UTHR) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher, or PPRV, to a subsidiary of AbbVie (ABBV). United Therapeutics received the PPRV when Unituxin was approved by the FDA for the treatment of neuroblastoma, a rare pediatric disease. Upon closing of the transaction, United Therapeutics will receive $350M in cash in exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.